cue BIOtech, Inc. Enters Collaboration With Lundbeck To Discover Allosteric Modulators Of G-Protein Coupled Receptors

EVANSTON, Ill.--(BUSINESS WIRE)--Jan. 27, 2006--Cue Biotech, Inc. today announced a collaboration with H. Lundbeck A/S to discover and develop small molecule therapeutics targeting G-Protein Coupled Receptors, or GPCR, for disorders and diseases of the Central Nervous System (CNS). The companies will apply Cue Biotech’s Cue-Quest screening technology to multiple GPCR targets in their efforts to identify and develop novel small molecules that allosterically modulate important CNS targets. Under the terms of the agreement, Cue Biotech will receive R&D payments with the potential for additional payments based on the success of the programs.

MORE ON THIS TOPIC